Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Lifts WUXI APPTEC (02359.HK) TP to $158.5 w/ Rating Buy
Recommend 9 Positive 10 Negative 7 |
||||
|
||||
|
Citi Research issued a research report lifting its target prices for WUXI APPTEC (02359.HK)'s H-/ A-shares from $156/ RMB138 to $158.5/ RMB140, with ratings at Buy, reflecting a 2% upward revision to revenue and EPS forecasts, based on Citi Research's optimistic outlook for Eli Lilly and Company (LLY.US)'s tirzepatide and orforglipron projects. The broker estimated that these projects will drive robust growth in WUXI APPTEC's TIDES business, forecasting a 40% YoY growth rate for the segment in 2026. Citi Research also estimated that, if orforglipron is launched in China in 2027, PHARMARON (03759.HK) will benefit, as its cooperation with Eli Lilly could further expand from orforglipron DP manufacturing in China. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
